Tafamidis
- Generic Name
- Tafamidis
- Brand Names
- Vyndamax, Vyndaqel
- Drug Type
- Small Molecule
- Chemical Formula
- C14H7Cl2NO3
- CAS Number
- 594839-88-0
- Unique Ingredient Identifier
- 8FG9H9D31J
- Background
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal.
Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
- Indication
Tafamidis is indicated to treat cardiomyopathy of wild type or hereditary transthyretin-mediated amyloidosis in adults.
- Associated Conditions
- Cardiomyopathy
This Study Will Examine the Clinical Effectiveness of Tafamidis in Patients With Mixed Phenotype Hereditary Transthyretin Amyloidosis
- Conditions
- Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2023-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 10
- Registration Number
- NCT05139680
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
The Effect of Tafamidis on Transthyretin Stabilization, Safety, Tolerability and Efficacy in Transthyretin Amyloid Polyneuropathy Patients
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2021-07-15
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 10
- Registration Number
- NCT04963985
- Locations
- 🇨🇳
Peking University Third Hospital, Beijin, China
The Effect Of Tafamidis Meglumine In Transthyretin Amyloid Polyneuropathy Patients
- Conditions
- Transthyretin Amyloid Polyneuropathy (ATTR-PN)
- Interventions
- First Posted Date
- 2021-04-02
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT04828993
- Locations
- 🇨🇳
Peking union hospital of Chinese academy of medical sciences, Beijing, China
🇨🇳Tiantan Hospital Capital Medical University, Beijing, China
🇨🇳Peking University First Hospital, Beijing, Beijing, China
A Study to Assess the Safety and Efficacy Of Tafamidis In Chinese Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
- First Posted Date
- 2021-03-24
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 53
- Registration Number
- NCT04814186
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
🇨🇳Peking Union Medical College Hospital, Beijing, Beijing, China
🇨🇳The Second Xiangya Hospital of Central South University, Changsha, Hunan, China
Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy
- Conditions
- ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- Interventions
- First Posted Date
- 2021-03-17
- Last Posted Date
- 2025-01-31
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 100
- Registration Number
- NCT04801329
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
A Study to Determine the Bioequivalence of Two Doses of Tafamidis
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2020-10-05
- Last Posted Date
- 2021-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT04575116
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Drug-Drug Interaction Study To Estimate The Effect Of Tafamidis On Rosuvastatin Pharmacokinetics
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04253353
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Bruxelles-capitale, Région DE, Belgium
Phase I Safety, Pharmacokinetics and Bioavailability Study Comparing Rate and Extent of Absorption of Two Different Forms of Tafamidis (PF-6291826)
- First Posted Date
- 2018-09-07
- Last Posted Date
- 2019-02-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT03662191
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study Comparing the Amounts of 2 Different Forms of Tafamidis (PF06291826), Both With and Without Food, In the Blood
- First Posted Date
- 2017-09-12
- Last Posted Date
- 2018-04-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT03280173
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
A Study Comparing Amounts of 2 Different Forms of Tafamidis (PF-6291826) in the Blood
- First Posted Date
- 2017-08-30
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 30
- Registration Number
- NCT03266705
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.